Inhomogeneous dose escalation for NSCLC: Full dosimetric analysis of the phase III NARLAL2 trial

被引：0
|
作者：
Lutz, Christina M. [1 ]
Nielsen, Tine B. [2 ]
Lund, Mikkel D. [3 ]
Schytte, Tine [2 ]
Hansen, Torben S. [3 ]
Hoffmann, Lone [1 ,4 ]
Ottosson, Katarina W. [5 ]
Peucelle, Cecile [6 ]
Rusten, Espen [7 ]
Levin, Nina [8 ]
Brink, Carsten [2 ]
Gronberg, Bjorn H. [8 ,9 ]
Haakensen, Vilde D. [7 ]
Hansen, Olfred [2 ]
Khalil, Azza A. [1 ,4 ]
Knap, Marianne M. [1 ]
Kristiansen, Charlotte [3 ]
Nielsen, Morten [2 ]
Persson, Gitte F. [5 ,10 ]
Pohl, Mette [6 ]
Thing, Rune S. [3 ]
Moller, Ditte S. [1 ,4 ]
机构：
[1] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
[2] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[3] Univ Hosp Southern Denmark, Vejle Hosp, Dept Oncol, Vejle, Denmark
[4] Aarhus Univ, Dept Clin Med, Aarhus, Denmark
[5] Copenhagen Univ Hosp Herlev & Gentofte, Dept Oncol, Herlev, Denmark
[6] Rigshosp, Dept Oncol, Copenhagen, Denmark
[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[8] St Olavs Hosp, Dept Oncol, Trondheim, Norway
[9] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway
[10] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
RADIOTHERAPY AND ONCOLOGY | 2024年 / 194卷
关键词：
NSCLC; dose escalation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2381
引用
收藏
页码：S1736 / S1739
页数：5
相关论文
共 50 条
  • [21] Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study
    Li, Juan
    Lu, Shun
    Tian, Yuke
    Jiang, Lan
    Li, Lu
    Xie, Shao-Hua
    Li, Qiang
    RADIOTHERAPY AND ONCOLOGY, 2024, 196
  • [22] Phase III trial of dose escalation using conformal radiotherapy in prostate cancer: Side effects and PSA control
    Dearnaley, D
    Hall, E
    Jackson, C
    Lawrence, D
    Huddart, R
    Eeles, R
    Gadd, J
    Warrington, A
    Bidmead, M
    Horwich, A
    BRITISH JOURNAL OF CANCER, 2001, 85 : 15 - 15
  • [23] Dosimetric explanations of fatigue in head and neck radiotherapy: An analysis from the PARSPORT Phase III trial
    Gulliford, Sarah L.
    Miah, Aisha B.
    Brennan, Sinead
    McQuaid, Dualta
    Clark, Catharine H.
    Partridge, Mike
    Harrington, Kevin J.
    Morden, James P.
    Hall, Emma
    Nutting, Christopher M.
    RADIOTHERAPY AND ONCOLOGY, 2012, 104 (02) : 205 - 212
  • [24] Prospective Phase 1/2 Clinical Trial: Evaluating Dose-Escalation for Esophageal Cancer
    Welsh, J. W.
    Seyedin, S. N.
    Hofstetter, W. L.
    Ajani, J. A.
    Chang, J. Y.
    Gomez, D. R.
    Swisher, S. G.
    Blum, M. A.
    Nguyen, Q.
    Minsky, B. D.
    Erasmus, J.
    Lee, J. H.
    Bhutani, M. S.
    Komaki, R. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S12 - S13
  • [25] Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
    Li, J.
    Li, Q.
    Lu, S.
    Jiang, L.
    Li, L.
    Xie, S. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S158 - S159
  • [26] Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial
    Wang, Si-Yang
    Xu, Xi-Wei
    Yao, Ji-Jin
    Peng, Pei-Jian
    Zhou, Bin
    Liu, Qiao-Dan
    Huang, Xiao-Ping
    Lin, Zhong
    TRANSLATIONAL ONCOLOGY, 2018, 11 (04): : 1007 - 1011
  • [27] Radiotherapy Dose Escalation in Unresectable Ewing's Sarcoma/ PNET: Final Results of a Phase III Randomized Controlled Trial
    Laskar, S.
    Sinha, S.
    Chatterjee, A.
    Khanna, N. R.
    Puri, A.
    Gulia, A.
    Nayak, P.
    Vora, T.
    Chinnaswamy, G.
    Prasad, M.
    Juvekar, S.
    Desai, S.
    Janu, A.
    Rangarajan, V.
    Purandare, N.
    Shah, S.
    Rekhi, B.
    Jambhekar, N.
    Muckaden, M. A.
    Kurkure, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S62 - S62
  • [28] A Phase 2 Dose and Volume De-escalation Trial for High- and Low-Risk HPV plus Oropharynx Cancer: Efficacy, Toxicity, and Dosimetric Analyses
    Melotek, J. M.
    Seiwert, T. Y.
    Blair, E. A.
    Foster, C. C.
    Karrison, T. G.
    Agrawal, N.
    Portugal, L.
    Gooi, Z.
    Stenson, K. M.
    Brisson, R. J.
    Arshad, S.
    Dekker, A.
    Spiotto, M. T.
    Villaflor, V. M.
    Vokes, E. E.
    Haraf, D. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S135 - S135
  • [29] A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients with Advanced NSCLC (NCI 10327): Results from Dose Escalation
    Riess, J.
    Frankel, P.
    Massarelli, E.
    Nieva, J.
    Lai, W. -C. V.
    Koczywas, M.
    Shackelford, D.
    Lanza, I.
    Reid, J. M.
    Gonsalves, W. I.
    Remick, A. J.
    Gandara, D. R.
    Piekarz, R.
    Lara, P. N.
    Newman, E.
    Villalona-Calero, M.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S91 - S92
  • [30] Quality of Life (QOL) Analysis of the Randomized Radiation (RT) Dose-Escalation NSCLC Trial (RTOG 0617): The Rest of the Story
    Movsas, B.
    Hu, C.
    Sloan, J.
    Bradley, J. D.
    Kavadi, V. S.
    Narayan, S.
    Robinson, C.
    Johnson, D. W.
    Paulus, R.
    Choy, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S1 - S2
12345